Drug intelligence / Profile preview

SBRX6

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBRX6 is a plant-based drug candidate developed by Stramsen Biotech for the treatment and management of asthma, allergies, and other respiratory conditions. As part of Stramsen's SBRX series, the candidate is developed using a natural botanical approach aimed at leveraging plant-derived compounds for therapeutic use. While the specific active ingredients, molecular targets, and mechanism of action have not been publicly disclosed, the drug is positioned within a pipeline of biopharmaceutical products targeting chronic inflammatory and respiratory diseases.

Beyond the preview

Go deeper on SBRX6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX6.

Explore the full profile